Quarter and Full-Year Financial Performance
Q4 2025: revenue growth +9%; adjusted EBITDA net of NCI +10%; adjusted EPS +20% vs Q4 2024. Full-year 2025: revenue growth +10%; adjusted EBITDA net of NCI +15%; adjusted EPS +31% vs 2024.
Strong Acute Care Operational Results
Same-facility Acute Care: net revenues +6.9% in Q4 (5.2% excl. insurance subsidiary); revenue per adjusted admission +5.4%; same-facility segment EBITDA +10.4% in Q4 with a 50 bps margin improvement to 14.8% (full-year margin +150 bps to 15.8%). Contract labor declined by 20 bps to 2.4% of Acute segment revenue.
Behavioral Health Revenue and Volume Recovery
Behavioral Health same-facility net revenues +7.2% in Q4, driven by revenue per adjusted patient day +5.6% and adjusted patient days +1.5%. Behavioral segment EBITDA +6.9% in Q4 and +7.8% for full year 2025.
Prudent Capital Allocation and Share Repurchases
2025 share repurchases: 4.65 million shares for $899 million (1.46 million shares bought in Q4). At 12/31/25, $1.425 billion of buyback authorization remained and ~$900 million of revolver capacity was available.
Growth Pipeline and Outpatient Expansion
Opened 2 acute hospitals over past 2 years; planned 3 inpatient expansions (178 beds) and a 156-bed de novo hospital in Palm Beach Gardens opening Q2 2026. Behavioral: 2 de novos (264 beds) in 2026; 119 outpatient behavioral locations including 10 new freestanding 1,000 Branches Wellness centers in 2025 and at least 10 more planned in 2026.
Technology and AI Adoption to Improve Efficiency
Deployed AI (Agentic AI) for post-discharge care to reduce readmissions; implemented AI-based revenue cycle tools for documentation and claims appeals; leveraging AI to streamline behavioral referral/intake — management cites measurable efficiencies and expects further benefits over coming quarters.
2026 Financial Guidance Reflects Continued Growth
2026 guidance: revenue $18.4B–$18.8B (+6%–8%); adjusted EBITDA net of NCI $2.64B–$2.79B (+2%–8%); adjusted net income per diluted share $22.64–$24.52 (+4%–13%). Assumes same-facility volume growth of 2%–3% and capex $950M–$1.1B.